su011248
Carcinoma, Small Cell Lung
National Cancer Institute (NCI)Phase 2Dormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Carcinoma, Small Cell Lung cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MITUMOMAB Eli Lilly and Company | Phase 3 | BB |
Tiragolumab Hoffmann-La Roche | Phase 3 | BB |
Epoetin Alfa Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | B |
Panobinostat Boundless Bio, Inc. | Phase 2 | B |
azd6244 National Cancer Institute (NCI) | Phase 2 | B |
View all 15 →
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →